diagnost tool
price close busi novemb
market leader non-invas blood-
base prenat test enter larg liquid
biopsi cancer organ transplant test market
beat remain top pick buy pt
continu execut high level year result came
pre-announc led volum growth day week away
like receiv final medicar coverag decis blood-bas kidney transplant
reject test prospera expect receiv final medicar coverag decis
first cancer signatera indic colon cancer around reiter
one top pick reiter buy rais pt
solid beat underli trend solid rev y/
beat pre-announce our/street prior aid
payment partner bgi volum y/i q/q match
pre-announce beat prior panorama nipt test
y/i beat estim horizon volum y/i beat
gm beat help bgi payment
volum growth impli build leadership posit despit
investor concern rise competit rev/test grew q/q
cogs/test significantli
recent rais nice de-risk balanc sheet view wise ad
anoth cash balanc sheet recent secondari offer beef
pro-forma cash million provid compani ampl room scale
busi primarili scale brand new transplant oncolog busi
transplant expect commerci launch prospera kidney test
medicar draft lcd turn final come week call announc
launch proactiv trial patient registri studi kidney largest
kind also launch second prospect multi-cent trial site
evercord divestitur sold newer evercord cord blood busi
ntm rev believ grow valu new transplant oncolog
busi render cord blood busi lower prioriti thu posit
decis divest focu much larger new market opportun
model trim revenu estim reflect full year
reduct rev cord blood divestitur conservat trim outlook
oncolog revenu bake transplant revenu estim
everi point share gain transplant add revenu model
transplant rev
colon cancer expect final decis colon cancer summer
peg monitor market alon tests/year signatera test
guid effect narrow wide revenu guid
report equiv pro-forma sale evercord busi
expect guid earn call like march
us novemb pleas host dynam
public privat held growth compani firesid chat investor
meet annual canaccord genuiti medic technolog diagnost
forum nyc contact canaccord repres detail
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
rais pt make sever updat valuat
framework rais price target use
higher multipl slightli lower revenu estim reflect revenu
divestitur cord blood busi higher share count follow recent
secondari offer pt use multipl revenu estim
discount back two year discount rate dilut share
outstand formerli pt use multipl revenu estim
discount back two year discount rate dilut share
model primarili reflect revenu beat rais revenu estim
primarili reflect full-year divestitur evercord
busi revenu lower revenu estim
y/i lower revenu estim
y/i prior estim primarili reflect beat
gm relat bgi payment rais gm reiter
gm estim rais gm estim
note gross margin estim conserv reflect improv
relat expect expans average-risk nipt microdelet test
transplant oncolog revenu primarili conservat lower
oncolog revenu estim previous expect mayb
half year revenu relat medicare-reimburs colon cancer monitor
signatera assay addit revenu relat ruo partnership revenu
expect monitor reimburs turn final around mid-year
first time introduc transplant revenu model
estim prospera kidney transplant revenu million model
ramp estim everi point share gain build
kidney transplant test add revenu base convers
manag first year revenu relat clinic patient test
prospera test manag confid gener revenu relat
proactiv trial patient registri studi kidney largest kind
also launch second prospect multi-cent trial site
recent rais import de-risk balanc sheet octob
price secondari offer issu share
anoth total share million gross
proce need money view decis rais money
wise investor ceas worri balanc sheet
direct time energi advanc major growth initi ahead new
transplant oncolog busi rais also provid flexibl
potenti make bolt-on acquisit two either relat technolog possibl
distribut side view end cash balanc
million secondari octob estim pro-forma cash balanc
average-risk nipt acog clear model zero new revenu gross
margin expect expans average-risk nipt thu think acog
amend prompt us significantli rais revenu gross margin estim
current level indic new guidanc way
support averag risk nipt still wait acog publish new
bulletin engag aet think expand coverag
polici decis average-risk nipt inevit present model
posit endors acog coverag aet average-risk
birth thu posit develop would addit estim
beyond estim increment revenu full-
year run-rat basi obtain obtain expand coverag health plan
aet
microdelet smart trial anoth catalyst remind
present obtain tini amount reimburs revenu relat
read sometim read-out think good probabl
insur aet elect pay microdelet test estim
buy unchang target price novemb
diagnost tool
could captur increment full-year run-rat basi
obtain expand coverag decis
fmi new oncolog partnership foundat medicin fmi initi
target co-develop new ctdna treatment monitor assay use
biopharma trial start later clinic use new co-develop
assay deploy advanced-canc set stage patient
believ -fmi partnership win-win foundat medicin
view abil fmi sale rep market monitor assay addit
flagship foundationon tissu test significantli strengthen commerci portfolio
enabl fmi competit cgp player like buy-rat
gh cari life scienc privat tempu privat other
four commerci channel cancer segment oncolog channel
direct clinic channel hire may scale rep
direct pharma channel bgi genom plan launch signatera
china foundat medicin fmi global partnership announc
septemb
expect expand develop reimburs across solid tumor
cancer state sit rich bodi data highlight strong util monitor
assay addit colon includ breast cancer sensit specif
publish clinic cancer research bladder cancer sensit
specif publish journal clinic oncolog lung cancer
sensit specif confid signatera monitor assay
use across dozen solid tumor cancer state yet publish data
cancer typer receiv draft coverag decis
one cancer type colon cancer expect continu gener
evid across cancer state expect commerci coverag decis
come across cancer type next year time believ
gener revenu oncolog pre-nat test though
take year play
buy unchang target price novemb
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price novemb
diagnost tool
buy unchang target price novemb
diagnost tool
buy unchang target price novemb
diagnost tool
